Sermorelin vs Tesamorelin: GHRH Analogs Compared

What are sermorelin and tesamorelin?

Both are synthetic GHRH analogs that prompt the pituitary gland to secrete growth hormone on its own schedule. Sermorelin is a 29-amino-acid fragment (GHRH 1-29), the shortest sequence that keeps GHRH activity. Tesamorelin is a modified GHRH analog engineered for a more stable signal, and it is the only one of the two with FDA approval, marketed as Egrifta for reducing excess visceral abdominal fat in a specific patient population (Falutz et al., 2007).

Because they act upstream on the pituitary rather than supplying growth hormone directly, both are described in the literature as GH secretagogues of the releasing-hormone class, distinct from ghrelin-receptor agonists such as ipamorelin (Raun et al., 1998).

How do their evidence bases compare?

Tesamorelin has the deeper and more recent clinical record; sermorelin's strongest published data is older and diagnostic. Tesamorelin's pivotal phase 3 data appeared in a major journal and showed a measured, placebo-controlled effect on visceral fat (Falutz et al., 2007). Sermorelin's reviewed human literature centers on its use as a growth-hormone stimulation and diagnostic agent and in pediatric growth contexts (Prakash and Goa, 1999), not on the body-composition uses it is often marketed for today.

What did the tesamorelin trial actually report?

In the phase 3 trial, the tesamorelin arm reduced visceral adipose tissue by about 15 percent over the study period, while the placebo arm increased, a difference measured by imaging in the trial population studied (Falutz et al., 2007). That within-arm figure is not a promise of results for any individual. The finding is the basis for tesamorelin's regulatory approval for reducing excess visceral abdominal fat in the approved population.

The two analogs also differ in how long they stay active. Sermorelin, as a short GHRH(1-29) fragment, is cleared quickly and has a brief functional half-life, whereas tesamorelin is stabilized against enzymatic breakdown so its signal lasts longer, which fits its once-daily dosing (Falutz et al., 2007). Related GHRH-analog work has shown that sustained GH and IGF-1 elevation is achievable with long-acting analogs in this general class (Teichman et al., 2006, on CJC-1295), which helps explain why analog design and duration of action matter for the observed effect.

What does research report about dosing?

The following reflects what published research reported, not a recommendation. Personal dosing decisions route to a qualified clinician.

Note the asymmetry: tesamorelin has a specific, trial-defined regimen tied to a measured outcome, while sermorelin's reviewed literature does not support a comparable body-composition dosing standard. Do not read either row as guidance for use.

How do their side-effect and safety profiles compare?

Tesamorelin's safety data comes from controlled trials; sermorelin's comes largely from older diagnostic use. In the tesamorelin program, reported effects included injection-site reactions and changes tied to GH-axis stimulation, and the trial monitored IGF-1 and glucose parameters (Falutz et al., 2007). For context on the GH-axis class more broadly, agents that raise GH signaling have been shown to affect glucose handling: the oral secretagogue MK-677 raised fasting glucose and lowered insulin sensitivity in one study (Nass et al., 2008), which is a reason clinical monitoring of glucose is discussed with GH-axis compounds generally.

Sermorelin's reviewed profile reflects its diagnostic and pediatric use and is described as generally well tolerated in that setting (Prakash and Goa, 1999), but that context differs from the fat-loss uses now marketed, where controlled long-term human data is limited.

Which has the stronger claim to real-world evidence?

Tesamorelin, by a clear margin, based on approval status and controlled trial data. It is FDA-approved and backed by a phase 3 outcome (Falutz et al., 2007). Sermorelin remains a real GHRH analog with a legitimate diagnostic history (Prakash and Goa, 1999), but its evidence for the body-composition uses it is often promoted for is thin and dated. For a deeper read on the approved compound, see the tesamorelin guide linked below.